Mp09-04 a Prospective Multicenter Clinical Trial for Efficacy of Mobile Uroflowmetry in Benign Prostatic Hyperplasia Undergoing Transurethral Resection: Interim Results

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology, Evaluation & Medical Non-surgical Therapy (MP09)1 May 2024MP09-04 A PROSPECTIVE MULTICENTER CLINICAL TRIAL FOR EFFICACY OF MOBILE UROFLOWMETRY IN BENIGN PROSTATIC HYPERPLASIA UNDERGOING TRANSURETHRAL RESECTION: INTERIM RESULTS Sang Hun Song, Jungwon Park, Jungkeun Song, Yeonsoo Jeong, Hoyoung Ryu, Jeong Woo Lee, and Sangchul Lee Sang Hun SongSang Hun Song , Jungwon ParkJungwon Park , Jungkeun SongJungkeun Song , Yeonsoo JeongYeonsoo Jeong , Hoyoung RyuHoyoung Ryu , Jeong Woo LeeJeong Woo Lee , and Sangchul LeeSangchul Lee View All Author Informationhttps://doi.org/10.1097/01.JU.0001008920.55771.18.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To assess the precision of a mobile application-based uroflowmetry (UFM) and compare it to inpatient UFM measurements for the management of patients undergoing surgical treatment for benign prostatic hyperplasia (BPH). METHODS: A total of 41 patients without prior treatment within 4 weeks of their initial outpatient clinic visit were prospectively enrolled from three tertiary centers. After diagnosis, participants with BPH conducted subsequent UFM measurements using a sound-based mobile application proudP® for at least 4 days during the pre-treatment period, followed by transurethral resection of prostate (TURP). Additional measurements were taken for 4-day periods after 2, 6, and 12 weeks of treatment initiation, with concurrent in-office measurements. UFM parameters, including maximum flow rate (Qmax) and voided volume (VV), were compared. Patient satisfaction was evaluated using a 0-10 scale at the end of the 12-week study. RESULTS: TURP resulted IPSS improvement of mean 18.0±8.0 to 7.8±6.6 at 12-weeks, reflected in mean Qmax improvement of 11.2 mL/sec by in-office measurements and well-correlated with mean improvement of 7.5 mL/sec by application. A statistically significant correlation (correlation coefficient 0.707, p<0.05) was observed between the two methods. The application-based UFM effectively reflected the improvement in voiding symptoms over time subsequent to the initiation of medical treatment, with sequential increase of mean Qmax. Sub-analysis by prostate size (<80 cc vs. ≥80 cc) showed better correlation in larger prostates, with good correlation regardless of initial IPSS severity. Overall, the participants reported a high level of satisfaction, with a mean score of 9.4±0.9 points at study completion. CONCLUSIONS: The findings of this study demonstrate that application-based UFM (proudP®) measurements serve as an accurate and reliable indicator of perioperative surveillance in patients undergoing TURP for BPH. By enabling a personalized and portable UFM, clinicians can easily monitor treatment response as well as observe risk of postoperative AUR. Download PPT Source of Funding: This work was supported by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (Project Number: 1711138269, RS-2020-KD000141) (NTIS, RS-2020-KD000141) © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e127 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Sang Hun Song More articles by this author Jungwon Park More articles by this author Jungkeun Song More articles by this author Yeonsoo Jeong More articles by this author Hoyoung Ryu More articles by this author Jeong Woo Lee More articles by this author Sangchul Lee More articles by this author Expand All Advertisement PDF downloadLoading ...